Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

5-HT antagonists in development at Synthelabo for cardiovascular and other disorders

Nov. 18, 1998

Synthesis and use of novel ET-antagonist series disclosed by Merck KGaA

Nov. 18, 1998

Cytel receives FDA grant to further development of selectin inhibitor

Nov. 18, 1998

Collateral Therapeutics draws nearer to an effective gene therapy for CHF

Nov. 17, 1998

Na+/Ca2+ exchange inhibitors patented by Taisho

Nov. 16, 1998

More news from AHA: azimilide prevents atrial fibrillation

Nov. 16, 1998

New cytokine modulator from Schering-Plough is active in models of endotoxemia

Nov. 13, 1998

Renal protective effect of efonidipine in hypertensive patients

Nov. 13, 1998

Serum complement activation is implicated in the pathogenesis of CHF

Nov. 13, 1998

BG-9719 has potent natriuretic effects in patients with CHF

Nov. 13, 1998

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...